BR0213183A - Uso de ativadores gp130 em neuropatia diabética - Google Patents

Uso de ativadores gp130 em neuropatia diabética

Info

Publication number
BR0213183A
BR0213183A BR0213183-8A BR0213183A BR0213183A BR 0213183 A BR0213183 A BR 0213183A BR 0213183 A BR0213183 A BR 0213183A BR 0213183 A BR0213183 A BR 0213183A
Authority
BR
Brazil
Prior art keywords
diabetic neuropathy
activators
medicament
prevention
manufacture
Prior art date
Application number
BR0213183-8A
Other languages
English (en)
Inventor
Michel Dreano
Pierre-Alain Vitte
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0213183A publication Critical patent/BR0213183A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE ATIVADORES gp130 EM NEUROPATIA DIABéTICA". A presente invenção refere-se ao uso de uma substância que sinaliza através da gp130 para a fabricação de um medicamento para o tratamento e/ou prevenção de neuropatia diabética. O uso de IL-6 é preferido.
BR0213183-8A 2001-10-11 2002-10-10 Uso de ativadores gp130 em neuropatia diabética BR0213183A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123400 2001-10-11
PCT/EP2002/011364 WO2003033015A1 (en) 2001-10-11 2002-10-10 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY

Publications (1)

Publication Number Publication Date
BR0213183A true BR0213183A (pt) 2004-08-31

Family

ID=8178778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213183-8A BR0213183A (pt) 2001-10-11 2002-10-10 Uso de ativadores gp130 em neuropatia diabética

Country Status (20)

Country Link
US (3) US7465441B2 (pt)
EP (1) EP1434597B1 (pt)
JP (1) JP2005505608A (pt)
KR (1) KR20050035151A (pt)
CN (1) CN1602203A (pt)
AT (1) ATE542542T1 (pt)
AU (1) AU2002340547B2 (pt)
BR (1) BR0213183A (pt)
CA (1) CA2463020A1 (pt)
DK (1) DK1434597T3 (pt)
EA (1) EA006881B1 (pt)
ES (1) ES2381341T3 (pt)
HR (1) HRP20040292A2 (pt)
IL (1) IL161310A0 (pt)
MX (1) MXPA04003442A (pt)
NO (1) NO20041908L (pt)
PL (1) PL369296A1 (pt)
WO (1) WO2003033015A1 (pt)
YU (1) YU29804A (pt)
ZA (1) ZA200402351B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU29804A (sh) * 2001-10-11 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba aktivatora gp-130 u dijabetskoj neuropatiji
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
AU2011203356B2 (en) * 2004-04-29 2012-03-22 Yeda Research & Development Co., Ltd IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) * 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
AU2008234408B2 (en) * 2007-03-30 2013-06-13 Baker Medical Research Institute Treatment of obesity
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN106924736B (zh) * 2017-05-09 2020-01-03 北京师范大学 gp130抑制剂在制备干预和治疗肥胖导致的血糖代谢疾病产品中的应用
FR3080533A1 (fr) * 2018-04-27 2019-11-01 Enterosys Utilisation de l'il-6 pour le traitement du diabete
WO2025188663A1 (en) * 2024-03-06 2025-09-12 Sonnet BioTherapeutics, Inc. Methods for the treatment of diabetes-associated autonomic neuropathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
YU29804A (sh) * 2001-10-11 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba aktivatora gp-130 u dijabetskoj neuropatiji

Also Published As

Publication number Publication date
YU29804A (sh) 2006-08-17
US20050058623A1 (en) 2005-03-17
PL369296A1 (en) 2005-04-18
IL161310A0 (en) 2004-09-27
NO20041908L (no) 2004-05-10
JP2005505608A (ja) 2005-02-24
ES2381341T3 (es) 2012-05-25
US8278286B2 (en) 2012-10-02
US20100189684A1 (en) 2010-07-29
WO2003033015A1 (en) 2003-04-24
EP1434597B1 (en) 2012-01-25
HRP20040292A2 (en) 2005-06-30
EP1434597A1 (en) 2004-07-07
EA200400520A1 (ru) 2004-08-26
CA2463020A1 (en) 2003-04-24
ZA200402351B (en) 2005-03-29
KR20050035151A (ko) 2005-04-15
US7465441B2 (en) 2008-12-16
AU2002340547B2 (en) 2008-04-03
US20090169506A1 (en) 2009-07-02
EA006881B1 (ru) 2006-04-28
MXPA04003442A (es) 2004-07-08
DK1434597T3 (da) 2012-02-27
ATE542542T1 (de) 2012-02-15
CN1602203A (zh) 2005-03-30

Similar Documents

Publication Publication Date Title
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
NZ544472A (en) Compounds and therapeutical use thereof
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0110028A (pt) Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
BR0213183A (pt) Uso de ativadores gp130 em neuropatia diabética
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
SE0102716D0 (sv) Novel compounds
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
MXPA04001912A (es) Aminobenzofenonas novedosas.
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
SE0102910D0 (sv) New use
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
DE60135454D1 (de) Pharmazeutische gel-zusammensetzung
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
DE69838686D1 (de) Tripeptidylpeptidaseinhibitoren

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/20 (2006.01), A61K 38/17 (2006.01), A61P 2